Skip to main content

$11.22 -0.22 (-1.92%)

High

$11.49

Low

$11.20

Trades

4,718

Turnover

$7,499,551

Volume

664,557
30 June 2023 at 4:12pm
Register to track TLX and receive email alerts.

ASX Announcements (7d)

-

Twitter Mentions (7d)

0+

AFR Articles (7d)

-

News Articles (7d)

4+
Subject
TLX Ann: 2022 Interim Report

TLX Ann: Appendix 4D - Results for announcement to the market

TLX Ann: Grand Pharmaceutical Group's investment in Telix

TLX Article: China’s Grand Decade drops $73m Telix stake, JPM seeks buyers

TLX Ann: Telix 1H 2022 Financial Results Investor Call Notification

TLX Article: Fund managers back market darling Telix Pharmaceuticals

TLX Ann: APAC Regulatory Progress Prostate and Kidney Cancer Imaging

TLX Ann: Appendix 4C and Activities Report for June 2022 Quarter

TLX Ann: Kevin Richardson appointed as CEO, Telix Americas

TLX Ann: Zircon Kidney Cancer Imaging Study completes Enrollment

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Distribution Agreement with Isologic for Illuccix in Canada

TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act 2001

TLX Ann: Notification regarding unquoted securities - TLX

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: Expansion of Partnership with RefleXion for Prostate Cancer

TLX Ann: Presentation to Jefferies Global Healthcare Conference

TLX Ann: Telix receives AUD$17.25 million R&D tax refund

TLX Ann: App 3Y Change in Director interests - T Olson

TLX Ann: Leadership changes including Darren Smith appointment as CFO

TLX Ann: Illuccix Reimbursement Milestone and Launch Updates

TLX Ann: Notification regarding unquoted securities - TLX

TLX Ann: App 3Y - Change in Directors Interests - C Behrenbruch

TLX Ann: App 3Y - Change in Directors Interests - T Olson

TLX Ann: App 3Z - Final Directors Interests Notice - O Buck

TLX Ann: Results of 2022 Annual General Meeting

TLX Ann: CEO's Address to AGM

TLX Ann: Chairman's Address to Annual General Meeting

TLX Ann: AGM - change to proposed amendments to Telix Constitution

TLX Ann: Appendix 3Y - Change in Directors Interests - O Buck

TLX Ann: Appendix 4C and Activities Report for March 2022 quarter

TLX Ann: Securities Dealing Policy - adopted 11 April 2022

TLX Ann: 2022 AGM Notice of Meeting, Proxy Form and Online Guide

TLX Ann: ProstACT TARGET Phase II Study Ethics Approval

TLX Ann: Telix Enters Licence Agreement with Lilly for Olaratumab

TLX Ann: Notification regarding unquoted securities - TLX

TLX Ann: Telix, GMS & Monash Awarded $23 million Federal Funding

TLX Ann: Commercial Launch - Illuccix Now Available to Order in US

TLX Ann: Appendix 3X - Initial Directors Interest Notice

TLX Ann: Change of Composition of the Telix Board of Directors

TLX Ann: FDA Orphan Drug Designation for Bone Marrow Conditioning

TLX Ann: Telix and Xiel Sign U.K. and Ireland Distribution Agreement

TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Development of Glioblastoma Therapy Program

TLX Ann: Radiopharmaceutical Production Facility Buildout Commences

TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Notice Required Under ASX Listing Rule 3.13.1

Register to track TLX and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC